Adalimumab/certolizumab-pegolTuberculosis: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1826卷 / 1期

关键词：

D O I：

10.1007/s40278-020-84467-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：20 / 20

相关论文

共 50 条

[21] Adalimumab/infliximabDermatomycoses: 2 case reports
Reactions Weekly, 2012, 1390 (1) : 6 - 6
[22] Adalimumab/etanerceptSarcoidosis?: 2 case reports
Reactions Weekly, 2010, 1290 (1) : 5 - 5
[23] Adalimumab/etanerceptTuberculosis: 2 case reports
Reactions Weekly, 2013, 1434 (1) : 5 - 5
[24] Adalimumab/etanerceptAsthma: 2 case reports
Reactions Weekly, 2016, 1583 (1) : 37 - 37
[25] Adalimumab/golimumabThyroiditis: 2 case reports
Reactions Weekly, 2015, 1557 (1) : 20 - 20
[26] Adalimumab/certolizumab pegol/etanercept/infliximabTuberculosis and immune reconstitution inflammatory syndrome: 14 case reports
Reactions Weekly, 2016, 1600 (1) : 22 - 22
[27] Adalimumab/certolizumab pegol/infliximabPsoriasis: case report
Reactions Weekly, 2016, 1586 (1) : 23 - 23
[28] Certolizumab pegolDrug antibody formation: 2 case reports
Reactions Weekly, 2017, 1669 (1) : 70 - 70
[29] Certolizumab pegol/etanerceptVarious toxicities: 2 case reports
Reactions Weekly, 2017, 1651 (1) : 73 - 73
[30] Certolizumab-pegolLack of efficacy: 2 case reports
Reactions Weekly, 2021, 1841 (1) : 67 - 67

← 1 2 3 4 5 →